CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $304,848, lower than 95% of all stocks globally
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
677.53BKRW488.20M · vs all stocks (USD)
Revenue (TTM)
423.07MKRW304.85K · vs all stocks (USD)
52-Week Change
17.00%vs all stocks
Market Capitalization
677.53BKRW488.20M · vs all stocks (USD)
Enterprise Value
676.68BKRW487.59M · vs all stocks (USD)
Price to Book (MRQ)
4.68xvs Biotechnology peers
Enterprise to Revenue
1.60Kxvs Biotechnology peers
Enterprise to EBITDA
-67.16xvs Biotechnology peers
Gross Margin
53.30%vs Biotechnology peers
Operating Margin
-2689.92%vs Biotechnology peers
Return on Assets (TTM)
-17.84%vs Biotechnology peers
Return on Equity (TTM)
-20.72%vs Biotechnology peers
Revenue (TTM)
423.07MKRW304.85K · vs all stocks (USD)
Revenue per Share (TTM)
30.17KRWUpdated Aug 20, 2026Quarterly Revenue Growth
72.55%vs Biotechnology peers
Gross Profit (TTM)
-33.48MKRW-24.13K · vs all stocks (USD)
EBITDA (TTM)
0.00KRWvs all stocks (USD)
Net Income (TTM)
-12.09BKRW-8.71M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-18840.85%vs Biotechnology peers
Operating Cash Flow (TTM)
-13.92BKRW-10.03M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-12.09BKRW-8.71M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
423.07MKRWFY2025 · Dec 31, 2025Cost of Goods Sold
456.55MKRWFY2025 · Dec 31, 2025Gross Profit
-33.48MKRWFY2025 · Dec 31, 2025Operating Income
-12.20BKRW-8.79M · vs all stocks (USD)
Pre-tax Income
-12.09BKRWFY2025 · Dec 31, 2025Net Income
-12.09BKRWFY2025 · Dec 31, 2025EBIT
-11.38BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-10.08BKRWFY2025 · Dec 31, 2025Research & Development
8.09BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
1.31BKRWFY2025 · Dec 31, 2025Other Operating Expenses
101.33MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
529.54MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
707.13MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-12.09BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-15.39BKRWFY2025 · Dec 31, 2025Free Cash Flow
-15.70BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
7.98BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-12.09BKRWFY2025 · Dec 31, 2025Stock-based Compensation
366.17MKRWFY2025 · Dec 31, 2025Other Non-cash Items
177.58MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-477.77MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.37BKRWFY2025 · Dec 31, 2025Capital Expenditures
-311.90MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-12.07MKRWFY2025 · Dec 31, 2025Purchase of Investments
-46.85BKRWFY2025 · Dec 31, 2025Sale of Investments
2.40BKRWFY2025 · Dec 31, 2025Other Investing Activity
-314.98MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-45.08BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-711.33MKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-711.33MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
56.42BKRWFY2025 · Dec 31, 2025Shares Outstanding
16.55MSharesUpdated Aug 20, 2026% Held by Insiders
17.10%vs all stocks
% Held by Institutions
11.10%vs all stocks
Total Cash (MRQ)
24.82BKRW17.88M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.50KKRWUpdated Aug 20, 2026Total Debt (MRQ)
40.22BKRW28.98M · vs all stocks (USD)
Current Ratio (MRQ)
2.48xvs Biotechnology peers
Book Value per Share (MRQ)
8.75KKRWUpdated Aug 20, 2026Total Assets
67.75BKRW48.82M · vs all stocks (USD)
Total Current Assets
53.34BKRWFY2025 · Dec 31, 2025Total Liabilities
9.41BKRWFY2025 · Dec 31, 2025Total Non-current Assets
14.40BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
2.15BKRWFY2025 · Dec 31, 2025Total Current Liabilities
7.25BKRWFY2025 · Dec 31, 2025Cash
7.98BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
7.98BKRWFY2025 · Dec 31, 2025Other Short-term Investments
44.16BKRWFY2025 · Dec 31, 2025Accounts Receivable
416.76MKRWFY2025 · Dec 31, 2025Short-term Debt
5.52BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-120.00KRWFY2025 · Dec 31, 2025Long-term Debt
1.61BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
80.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
8.21BKRWFY2025 · Dec 31, 2025Retained Earnings
-141.17BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
58.34BKRW42.04M · vs all stocks (USD)
52-Week Low
22.40KKRWUpdated Aug 20, 202652-Week High
124.00KKRWUpdated Aug 20, 202652-Week Change
17.00%vs all stocks
50-Day MA
37.58KKRWUpdated Aug 20, 2026200-Day MA
68.17KKRWUpdated Aug 20, 2026Avg 10-Day Volume
154.37KSharesUpdated Aug 20, 2026Avg 30-Day Volume
146.74KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-862.00KRWUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $304,848, lower than 95% of all stocks globallySignificant
Revenue (USD): 304,847.982Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
ProKidney Corp
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Transtek Medical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chison Medical Technologies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
OrthoPediatrics Corp.
Tier 1ProductionApproval-Gated PipelineRule
Huaren Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Succeeder Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hyundai Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ZJ Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Onconic Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Neuromeka Co., Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated